Marco Demaria and Navitoclax (ABT-263)
Marco Demaria's dossier links him to navitoclax (ABT-263), a BCL-2 family inhibitor and benchmark senolytic administered to eliminate senescent cells, though the specific study and his role remain unidentified.
Marco Demaria is a group leader at ERIBA. His dossier holds one fragment: "The senolytic ABT263 was administered to eliminate senescent cells."
ABT-263, also called navitoclax, is a BCL-2 family inhibitor and a benchmark senolytic. Demaria's lab studies how cellular senescence affects tissue repair, aging, and age-related disease, and how senescent cells can be therapeutically targeted. The fragment fits that research directly.
The navitoclax entry on the platform separately describes a result: the compound ameliorated progressive lung fibrosis in immunodeficient mice engrafted with human senescent fibroblasts and was the only tested antifibrotic agent that showed senolytic activity. Whether that result comes from the same study as the dossier fragment is unclear from the available data.
The study itself is not identified: no title, no experimental model, no outcomes, no indication of Demaria's role.
The edge connects a researcher whose explicit focus is therapeutic targeting of senescent cells to a benchmark senolytic through a concrete experimental action, making the link substantively meaningful rather than nominal, while the honest limits on what the fragment actually establishes keep the post grounded.